The saying that the way to a man’s heart is through the stomach might be true in more ways than one. Diagnostics company LipoScience is developing a new cardiovascular disease test that would use gut flora as a biomarker for cardiovascular risks. The novel approach is based on research licensed from the Cleveland Clinic. Researchers […]
Diagnostics company LipoScience, which is in the midst of plans for an initial public stock offering, now has a new chief operating officer. Timothy Fischer joined LipoScience in 2010 as the company’s vice president of research and development. Now as COO, Fischer will continue overseeing R&D as well as commercial operations and medical affairs. Fischer […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Diagnostics firm LipoScience is seeking U.S. Food and Drug Administration clearance for a new lab-based technology platform that tests for heart disease risks. LipoScience has commercialized a blood test that measures the density of lipoproteins in a sample, a measure that the company says is a better gauge for cardiovascular disease than cholesterol tests. So […]
Diagnostics technology company LipoScience, in the midst of plans to go public as it builds commercialization efforts for its test for cardiovascular disease, now has a new chief medical officer. Dr. Robert Honigberg was named CMO and vice president of medical affairs for the Raleigh, North Carolina company. LipoScience has developed a blood test that […]
Diagnostics company LipoScience aims to become North Carolina’s next public company. Raleigh, North Carolina-based LipoScience has filed with securities regulators plans to raise up to $86.2 million in an initial public stock offering. It’s the second time LipoScience has flirted with a public stock offering. The company filed IPO plans in 2001, only to withdraw […]